Methods for reducing CD36 expression

Details Methods for reducing CD36 expression Methods for reducing CD36 expression

2009-05-01

2010-10-12

Bradley, Christina (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07811987

ABSTRACT:
The invention provides a method for reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pmis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, ptmay also be 1.

REFERENCES:
patent: 5312899 (1994-05-01), Schiller
patent: 5602100 (1997-02-01), Brown et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5885958 (1999-03-01), Zadina et al.
patent: 5993848 (1999-11-01), Suzuki et al.
patent: 5994372 (1999-11-01), Yaksh
patent: 6221355 (2001-04-01), Dowdy
patent: 6268398 (2001-07-01), Ghosh et al.
patent: 6503713 (2003-01-01), Rana
patent: 6703483 (2004-03-01), Schiller
patent: 6759520 (2004-07-01), Carr et al.
patent: 6900178 (2005-05-01), Oeltgen et al.
patent: 7498297 (2009-03-01), Szeto et al.
patent: 2004/0248808 (2004-12-01), Szeto et al.
patent: 2005/0096333 (2005-05-01), Dugar et al.
patent: 2005/0158373 (2005-07-01), Szeto et al.
patent: 2005/0192215 (2005-09-01), Ghosh et al.
patent: 2006/0084606 (2006-04-01), Szeto
patent: 2007/0015711 (2007-01-01), Szeto et al.
patent: 2007/0027070 (2007-02-01), Szeto et al.
patent: 2007/0027087 (2007-02-01), Szeto et al.
patent: 2007/0093969 (2007-04-01), Mendrick et al.
patent: 2007/0129306 (2007-06-01), Szeto et al.
patent: 2007/0259377 (2007-11-01), Urdea et al.
patent: 2008/0014604 (2008-01-01), Devarajan et al.
patent: 2008/0027082 (2008-01-01), Hocher et al.
patent: 2000/2361364 (2000-09-01), None
patent: WO-95/22557 (1995-08-01), None
patent: WO-00/55189 (2000-09-01), None
patent: WO-02/05748 (2002-01-01), None
patent: WO-2004/070054 (2004-08-01), None
patent: WO-2005/001023 (2005-01-01), None
patent: WO-2005/072295 (2005-08-01), None
patent: WO-2007/035640 (2007-03-01), None
Merck Manual Online entry for Nephrotic Disease, Jan. 2010.
Aitman et al., Identification of CD36 (Fat) as an insulin resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats,Nature Genetics, 21(1):76-83 (1999).
Azzouz, Mimoun, Gene therapy for ALS: progress and prospects,Biochemical et Biophysica Acta, 1762:1122-1127, 2006.
Berendsen, Herman, A glimpse of the holy grail?,Science, 282:642-643, Oct. 23, 1998.
Bickel et al., Synthesis and bioactivity of monobiotinylated DALDA: A Mu-specific opioid peptide designed for targeted brain delivery,J Pharmacol and Exp Therapeutics, 268(2): 791-796 (1994).
Bork et al., Go hunting in sequence databases but watch out for the traps,Trends in Genetics, 12:425-427, 1996.
Bork, Powers and pitfalls in sequence analysis: the 70% hurdle,Genome Research, 10:398-400, 2000.
Bradley et al., Limits of cooperativity in a structurally modular protein: response of the notch ankyrin domain to analogous alanine substitutions in each repeat,J. Mol. Biol., 324:373-386, 2002.
Brenner, Errors in genome annotation,Trends in Genetics, 15:132-133, 1999.
Broekemeier et al., Inhibition of the mitochondrial permeability transition by Cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases,Biochemistry, 34:16440-16449, 1995.
Citron, Martin, Alzheimer's Disease: Treatments in discovery and development,Nature Neuroscience Supplement, 5:1055-1057, Nov. 2002.
Clapp III et al., Cardiovascular and metabolic responses to two receptor-selective opioid agonists in pregnant sheep,American Journal of Obstetrics and Gynecology, 178(2):397-401, Feb. 1998.
Corpeleijin et al. Direct association of a promoter polymorphism in the CD36/FAT fatty acid transporter gene with Type 2 diabetes mellitus and insulin resistance,Diabet Med., 23(8):907-911 (2006).
Demas, et al., Anaesthesia for heart transplantation,Br J. Anaesth, 58:1357-1564, 1986.
Dimaio et al., Synthesis and pharmacological characterization in vitro of cyclic enkephalin analogues, Effect of Conformational Constraints on Opiate Receptor Selectivity,J. Med. Chem., 25:1432-1438, 1982.
Doerks et al., Protein annotation: detective work for function prediction,Trends in Genetics, 14:248-250, 1998.
Dooley, C T et al., Selective ligands for the mu, delta and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library,Journal of Biological Chemistry, American Society of Biochemistry and Molecular Biology, 273(30):18848-18856, Jul. 24, 1998.
Drin et al., Studies on the internalization mechanism of cationic cell-penetrating peptides,Journal of Biological Chemistry, 278(33):31192-31201, 2003.
Fuhrman et al., Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase,Atherosclerosis, 161(2):307-316, Mar. 7, 2002.
Guerrini et al., Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt] deltorphin B,European Journal of Pharmacology, 302:37-42, 1996 (abstract only.).
Herve et al., On the immunogenic properties of retro-inverso peptides. Total retro-inversion of t-cell epitopes causes a loss of binding to MHC II molecules,Molecular Immunology, 34(2):157-163, 1997.
Holsey et al., Cardiovascular effects of a μ-selective opioid agonist (Tyrosine-D-Arginine-Phenylalanine-Lysine-NH2) in fetal sheep; Sites and Mechanisms of Action,Am. J. Obstet. Gynecol., 180(5):1127-1130, May 1999.
International Search Report and Written Opinion in International Application No. PCT/US2006/036291, dated Sep. 24, 2007.
Kett et al., Baroreflex-mediated bradycardia but not tachycardia is blunted peripherally by intravenous μ-opioid agonists,Am. J. Obstet. Gynecol., 178(5):950-955, May 1998.
Korczyn et al., Emerging therapies in the pharmacological treatment of Parkinson's Disease,Drugs, 62(5):775-786, 2002.
Lasukova et al., Activation of mu-opioid receptors and cardiomyocyte resistance to free radical damage,Patol Fiziol Eksp Ter., 2: English Abstract Only, 2001.
Lishmanov et al., Ligands for opioid and o-receptors improve cardiac electrical stability in rat models of post-infarction cardiosclerosis and stress,Life Sciences, 65:13-17, 1999.
Majer et al., Synthesis of methylated phenylalanines via hydrogenolysis of corresponding 1, 2, 3, 4 tetrahydroisoquinoline-3-caraboxylic acids,Int. Journal of Peptide&Protein Research, 43:62-68, 1994.
Margolis et al., Diagnosis of Huntington Disease,Clinical Chemistry, 49(10):1726-1732, 2003.
Moosman et al. Secretory peptide hormones are biochemical antioxidants: structure-activity relationship,Mol Pharmacol, 61:260-268, 2002.
Neilan et al., Pharmacological characterization of the dermorphin analog [Dmt1]DALDA, a highly potent and selective u-opioid peptide,European Journal of Pharmacology, 419(1):15-23, 2001.
Ngo et al., Computational complexity, protein structure prediction, and the leventhal paradox, the protein folding problem and tertiary structure prediction, (Ed. K. Merz Jr. and S. Le Grand), Birkhauser Boston, 492-495, 1994.
Omoniyi et al., A peripheral site of action for the attenuation of baroreflex-mediated bradycardia by intravenous μ-opioid agonists,Journal of Cardiovascular Pharmocolgy™, 35(2):269-274, 2000.
Patel et al., Pharmacotherapy of cognitive impairment in Alzheimer's Disease: a review,J. Geriatr. Psychiatry Neurol., 8:81-95, 1995.
Richard et al., Cell-penetrating peptides,Journal of Biological Chemistry, 278(1):585-590, 2003.
Rudinger, J., Peptide hormones, (Ed. J. A. Parson), University Park Press, Baltimore, 1-7, 1976.
Schiller et al., Dermorphin analogues carrying an increased positive net charge in their “message” domain displa

Affiliated with

Also associated with

Rating

Methods for reducing CD36 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for reducing CD36 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing CD36 expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4162032